摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-pentyl-5-(phenylthio)-1,3,4-oxadiazole | 1298111-31-5

中文名称
——
中文别名
——
英文名称
2-pentyl-5-(phenylthio)-1,3,4-oxadiazole
英文别名
2-Pentyl-5-phenylsulfanyl-1,3,4-oxadiazole;2-pentyl-5-phenylsulfanyl-1,3,4-oxadiazole
2-pentyl-5-(phenylthio)-1,3,4-oxadiazole化学式
CAS
1298111-31-5
化学式
C13H16N2OS
mdl
——
分子量
248.349
InChiKey
BGXABYGLHSVOAP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    17
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    64.2
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    碘苯5-pentyl-1,3,4-oxadiazole-2-thionecopper(l) iodide1,10-菲罗啉potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 10.0h, 以97%的产率得到2-pentyl-5-(phenylthio)-1,3,4-oxadiazole
    参考文献:
    名称:
    铜催化杂环硫醇与芳基碘化物的C–S交叉偶联
    摘要:
    据报道,铜催化的杂环硫醇与芳基碘化物的交叉偶联。反应在120℃下在CuI(5mol%),1,10-菲咯啉(10mol%)和K 2 CO 3(1.3当量)的存在下在DMF中进行。以高选择性和高产率制备了各种杂环硫化物。
    DOI:
    10.1016/j.tet.2011.02.064
点击查看最新优质反应信息

文献信息

  • Substituted diazabicycloalkane derivatives
    申请人:Basha Anwer
    公开号:US20050101602A1
    公开(公告)日:2005-05-12
    Compounds of formula (I) Z-Ar 1 —Ar 2 (I) wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
    式(I)的化合物 Z-Ar 1 —Ar 2 (I) 其中Z是一种二氮杂双环胺,Ar 1 是一个5-或6-成员芳香环,Ar 2 选自未取代或取代的5-或6-成员杂芳基环;未取代或取代的双环杂芳基环;3,4-(亚甲二氧基)苯基;咔唑基;四氢咔唑基;萘基;和苯基;其中苯基在间位或对位上取代有0、1、2或3个取代基。这些化合物在治疗由α7 nAChR配体预防或改善的病症或紊乱中有用。还公开了包含式(I)的化合物的药物组合物以及使用这些化合物和组合物的方法。
  • [EN] SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS<br/>[FR] DERIVES DE DIAZABICYCLOALCANE SUBSTITUES UTILISES EN TANT QUE LIGANDS AU NIVEAU DES RECEPTEURS ALPHA 7 DE L'ACETYLCHOLINE NICOTINIQUE
    申请人:ABBOTT LAB
    公开号:WO2005028477A1
    公开(公告)日:2005-03-31
    Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
    化合物的公式(I)为Z-Ar1-Ar2,其中Z是一种二氮杂双环胺,Ar1是一种5-或6-成员的芳香环,而Ar2则选自于未取代或取代的5-或6-成员杂芳基环;未取代或取代的双环杂芳基环;3,4-(亚甲氧基)苯基;咔唑基;四氢咔唑基;萘基;以及苯基;其中苯基在间位或对位上取代有0、1、2或3个取代基。这些化合物在治疗由α7 nAChR配体预防或缓解的疾病或疾病状态中有用。此外,还披露了包含公式(I)化合物的制药组合物以及使用这些化合物和组合物的方法。
  • Substituted Diazabicycloalkane Derivates
    申请人:Frost Jennifer M.
    公开号:US20080275048A1
    公开(公告)日:2008-11-06
    Compounds of formula (I) Z-Ar 1 —Ar 2 (I) wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
    化合物的公式为(I)Z-Ar1—Ar2(I),其中Z是一种二氮杂双环胺,Ar1是一种5或6成员芳香环,而Ar2则选自未取代或取代的5或6成员杂芳基环;未取代或取代的双环杂芳基环;3,4-(亚甲氧基)苯基;咔唑基;四氢咔唑基;萘基;和苯基;其中苯基在间位或对位上取代有0、1、2或3个取代基。这些化合物在治疗由α7 nAChR配体预防或改善的疾病或疾病方面是有用的。此外,还披露了包含公式(I)化合物的制药组合物以及使用这些化合物和组合物的方法。
  • Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors
    申请人:Abbott Laboratories
    公开号:EP2316836A1
    公开(公告)日:2011-05-04
    Compounds of formula (I) Z-Ar1-Ar2 wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5-or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazoyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
    式(I) Z-Ar1-Ar2 的化合物 其中 Z 是重氮双环胺,Ar1 是 5 或 6 元芳香环,Ar2 选自由未取代或取代的 5 或 6 元杂芳环组成的组;未取代或取代的双环杂芳基环;3,4-(亚甲基二氧基)苯基;咔唑基;四氢咔唑基;萘基;和苯基;其中苯基在元位或对位被 0、1、2 或 3 个取代基取代。这些化合物可用于治疗被 α7 nAChR 配体预防或改善的病症或紊乱。还公开了包含式(I)化合物的药物组合物以及使用此类化合物和组合物的方法。
  • SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS
    申请人:ABBOTT LABORATORIES
    公开号:EP1664045A1
    公开(公告)日:2006-06-07
查看更多